Department of Pathology, Forensic Medicine and Cytology, Split University Hospital Centre, University of Split, School of Medicine, Spinčićeva 1, Split, Croatia.
Acta Histochem. 2013 May;115(4):344-8. doi: 10.1016/j.acthis.2012.09.006. Epub 2012 Sep 29.
Triple negative breast cancer (TNBC) consists of a group of tumors with poor prognosis, owing to aggressive tumor biology and lack of targeted therapy. The aim of this study was to assess the immunostaining for androgen receptors (ARs) in the group of TNBC, in addition to basal-like (BL) immunophenotype, BL morphology and conventional clinicopathological factors and to demonstrate its prognostic relevance in this group of tumors. The study included 83 patients. Slides were stained immunohistochemically for estrogen and progesterone receptors, HER2, CK5/6, CK14, EGFR, Ki-67 and AR. Of the 83 TNBC samples, 32.5% showed positive immunostaining for AR, 66.3% had BL immunophenotype, and 48.2% had BL morphology. Positive AR immunostaining was inversely correlated with higher clinical stage, higher mitotic score, higher histological grade and higher proliferation index measured by Ki-67. Significantly more AR negative tumors were observed among the tumors with BL immunophenotype and BL morphology. There was no significant association between positive AR immunostaining and disease free survival or overall survival. More than one third of TNBC were AR-positive, and this represents a potential opportunity for novel targeted treatment in the group of breast tumors for which therapeutic options are currently limited.
三阴性乳腺癌(TNBC)由一组预后不良的肿瘤组成,这归因于侵袭性肿瘤生物学和缺乏靶向治疗。本研究的目的是评估 TNBC 组中雄激素受体(AR)的免疫染色情况,此外还评估了基底样(BL)免疫表型、BL 形态和常规临床病理因素,并证明其在该组肿瘤中的预后相关性。该研究纳入了 83 名患者。对雌激素和孕激素受体、HER2、CK5/6、CK14、EGFR、Ki-67 和 AR 进行了免疫组织化学染色。在 83 例 TNBC 样本中,32.5%的样本 AR 免疫染色阳性,66.3%具有 BL 免疫表型,48.2%具有 BL 形态。AR 免疫染色阳性与较高的临床分期、较高的有丝分裂评分、较高的组织学分级和较高的 Ki-67 增殖指数呈负相关。在具有 BL 免疫表型和 BL 形态的肿瘤中,观察到更多的 AR 阴性肿瘤。AR 免疫染色阳性与无病生存或总生存无显著相关性。超过三分之一的 TNBC 是 AR 阳性的,这为目前治疗选择有限的乳腺癌组提供了新的靶向治疗的潜在机会。